Liquidia (NASDAQ:LQDA) Insider Sarah Krepp Sells 13,165 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 13,165 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $492,765.95. Following the completion of the sale, the insider directly owned 140,769 shares in the company, valued at approximately $5,268,983.67. This trade represents a 8.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sarah Krepp also recently made the following trade(s):

• On Monday, December 1st, Sarah Krepp sold 221 shares of Liquidia stock. The shares were sold at an average price of $32.19, for a total transaction of $7,113.99.

Liquidia Trading Up 4.1%

NASDAQ:LQDA opened at $38.09 on Wednesday. Liquidia Corporation has a 12 month low of $11.26 and a 12 month high of $39.29. The company has a 50-day moving average price of $32.14 and a 200-day moving average price of $25.58. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. The stock has a market cap of $3.31 billion, a price-to-earnings ratio of -26.45, a P/E/G ratio of 1.22 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. The company had revenue of $54.34 million during the quarter, compared to analysts’ expectations of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company’s revenue was up 1106.7% on a year-over-year basis. Equities analysts predict that Liquidia Corporation will post -1.51 EPS for the current year.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its stake in Liquidia by 46.7% during the 4th quarter. SG Americas Securities LLC now owns 54,696 shares of the company’s stock valued at $1,886,000 after purchasing an additional 17,407 shares during the last quarter. Insight Wealth Strategies LLC bought a new position in shares of Liquidia during the fourth quarter valued at $4,891,000. Tudor Investment Corp ET AL purchased a new stake in shares of Liquidia during the third quarter valued at $1,536,000. FNY Investment Advisers LLC purchased a new stake in shares of Liquidia during the third quarter valued at $34,000. Finally, Caxton Associates LLP bought a new stake in Liquidia in the 3rd quarter worth about $389,000. 64.54% of the stock is owned by institutional investors.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined about 18.1% to ~10.71M shares as of Dec. 31 (about 17.6% of shares outstanding), lowering potential downward pressure from short sellers and reducing immediate squeeze risk.
• Neutral Sentiment: Reported short-interest data for Jan. 12 appears inconsistent (shows 0 shares / NaN change), which looks like a reporting glitch and should be treated as unreliable until corrected.
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average of $37.43 for roughly $2.49M, reducing his direct stake by ~6.0%. SEC Filing – Roger Jeffs
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 for about $1.38M, a ~9.5% reduction in his holding. SEC Filing – Michael Kaseta
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 for about $1.02M, a ~4.5% stake reduction. SEC Filing – Russell Schundler
• Negative Sentiment: Insider Rajeev Saggar sold 21,142 shares at $37.43 (~$791k), cutting his holdings by ~10.7%. SEC Filing – Rajeev Saggar
• Negative Sentiment: Scott Moomaw sold 20,533 shares at $37.43 (~$769k), an ~11.7% reduction in his stake. SEC Filing – Scott Moomaw
• Negative Sentiment: CAO Dana Boyle sold 11,047 shares at $37.43 (~$413k), a ~6.6% reduction. SEC Filing – Dana Boyle
• Negative Sentiment: Insider Jason Adair sold 13,548 shares at $37.43 (~$507k), and Sarah Krepp sold 13,165 shares (~$493k); both reduced holdings by mid-single-digit to high-single-digit percentages. SEC Filing – Jason Adair SEC Filing – Sarah Krepp

Wall Street Analysts Forecast Growth

Several research firms recently commented on LQDA. BTIG Research reissued a “buy” rating and set a $49.00 price objective on shares of Liquidia in a research note on Friday. Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday. Needham & Company LLC raised their price objective on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Raymond James Financial reissued a “strong-buy” rating and issued a $47.00 target price on shares of Liquidia in a report on Tuesday, November 4th. Finally, HC Wainwright increased their target price on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and an average target price of $39.67.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).